Freeman Chris 4
4 · Guardant Health, Inc. · Filed Mar 13, 2026
Research Summary
AI-generated summary of this filing
Guardant Health (GH) CCO Chris Freeman Receives RSU Award
What Happened
Chris Freeman, Chief Commercial Officer of Guardant Health (GH), was granted 18,744 restricted stock units (RSUs) on March 11, 2026. The award was recorded as an acquisition at $0.00 (typical for RSU grants); no cash changed hands at grant.
Key Details
- Transaction type: A (award/grant) — 18,744 RSUs granted on 2026-03-11 at $0.00 per share.
- Vesting: 33% vests on April 1, 2027; the remaining 67% vests in equal quarterly installments over the following two-year period (see footnote F1).
- Shares owned after transaction: Not specified in the Form 4.
- Tax/withholding note: Footnote F2 indicates "Not applicable for Restricted Stock Units."
- Filing: Form 4 filed 2026-03-13 (appears timely relative to the 2026-03-11 grant).
Context
This was a compensation award (RSUs), not an open-market purchase or sale. RSU grants are common executive compensation and vest over time, so they do not represent an immediate sale or purchase signal. The reported transaction is a derivative award that converts to ordinary shares as the RSUs vest.
Insider Transaction Report
Form 4
Freeman Chris
Chief Commercial Officer
Transactions
- Award
Restricted Stock Units
[F1][F2]2026-03-11+18,744→ 18,744 totalExercise: $0.00→ Common Stock (18,744 underlying)
Footnotes (2)
- [F1]This represents a restricted stock unit award granted on March 11, 2026 that vests over a three-year period. 33% of the shares subject to such award will vest on April 1, 2027 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
- [F2]Not applicable for Restricted Stock Units.
Signature
/s/ John G. Saia, as attorney-in-fact for Chris Freeman|2026-03-13